Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name (Ascending) Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68001-0437-25 68001-0437 Zoledronic acid Zoledronic acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous June 29, 2020 In Use
67457-0920-05 67457-0920 Zoledronic acid Zoledronic acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Oct. 12, 2020 In Use
47335-0401-81 47335-0401 abiraterone acetate YONSA 125.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral May 22, 2018 In Use
00378-6921-91 00378-6921 abiraterone acetate Abiraterone Acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Dec. 14, 2020 In Use
59212-0601-22 59212-0601 alitretinoin PANRETIN 60.0 mg/60g Hormonal Therapy Immunomodulator Retinoic Acid Derivative Topical Sept. 10, 2019 In Use
47426-0201-01 47426-0201 aprepitant CINVANTI 130.0 mg/18mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 3, 2018 In Use
50742-0438-10 50742-0438 arsenic trioxide ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 15, 2018 In Use
50742-0525-07 50742-0525 arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Jan. 27, 2021 In Use
00078-1091-20 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1091-94 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1098-20 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1098-30 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1098-94 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
81561-0413-05 81561-0413 asparaginase ERWINASE 10000.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous June 1, 2021 In Use
68727-0900-03 68727-0900 asparaginase erwinia chrysanthemi (recombinant)-rywn Rylaze 20.0 mg/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular June 30, 2021 In Use
72064-0110-30 72064-0110 avapritinib Ayvakit 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jan. 9, 2020 In Use
72064-0120-30 72064-0120 avapritinib Ayvakit 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jan. 9, 2020 In Use
72064-0125-30 72064-0125 avapritinib Ayvakit 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jan. 9, 2020 In Use
72064-0130-30 72064-0130 avapritinib Ayvakit 300.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jan. 9, 2020 In Use
72064-0150-30 72064-0150 avapritinib Ayvakit 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jan. 9, 2020 In Use
72485-0201-01 72485-0201 azacitidine AZACITIDINE 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 10, 2018 In Use
59572-0730-07 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 18, 2020 In Use
59572-0730-14 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2020 In Use
59572-0740-07 59572-0740 azacitidine ONUREG 300.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 18, 2020 In Use
59572-0740-14 59572-0740 azacitidine ONUREG 300.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2020 In Use

Found 10,000 results in 19 milliseconds — Export these results